Materials & Methods Exchange

Category	Tool/technique	Partner Name/Institution	Research Group Name	Institution	Email	Details
Materials	Cell lines and other biological material	Ago Rinken	GPCR group	University of Tartu, Institute of Chemistry, Estonia		Baculovirus systems for several GPCR
Materials	Cell lines and other biological material	Anna Ardévol	MoBioFood	Universitat Rovira i Virgili		Caco-2 and endocrine cell lines. Rats
Materials	Cell lines and other biological material	Domain Therapeutics	Drug Discovery			Transitent and stable
Materials	Cell lines and other biological material	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		some cell lines are inhouse, but are not allowed for sharing
Materials	Cell lines and other biological material	Humboldt-University of Berlin	Experimental Biophysics - Hegemann lab	Humboldt-University of Berlin		Usually under an MTA, if no further legal restrictions apply
Materials	Cell lines and other biological material	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		Various assays to detect cAMP, Calcium, arrestin or G protein binding.
Materials	Cell lines and other biological material	Tommaso Patriarchi / University of Zurich	Patriarchi	University of Zurich		Stable cell lines expressing a variety of genetically encoded biosensors for investigating ligand-induced GPCR activation
Materials	Cell lines and other biological material	Véronique Bozon/University of Tours	BIOS	INRAe/University of Tours
Materials	Compounds available in digital format for sharing upon request	Abdurrahman Olgac	Banoglu Research Group	Gazi University, Faculty of Pharmacy
Materials	Compounds available in digital format for sharing upon request	Eddy Sotelo	ComBioMed	CIQUS. University of Santiago de Compostela	e.sotelo	Part of the library is in digital formateando
Materials	Compounds available in digital format for sharing upon request	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		this sharing depends on the detailed request of the partner
Materials	Compounds available in digital format for sharing upon request	Marcel Bermudez	Molecular Design Lab (Wolber lab)	Freie Universität Berlin
Materials	Compounds available in digital format for sharing upon request	Nadine Jagerovic/Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute		cannabinoids and derivatives
Materials	Homology models or X-ray structures (unpublished) in digital format for sharing upon request	Antonios Kolocouris		National and Kapodistrian University of Athens		Adenosine receptors A3 and A2B
Materials	Homology models or X-ray structures (unpublished) in digital format for sharing upon request	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg		model of CCR5 dimers models of CCR5 in complex with different gp120s
Materials	Homology models or X-ray structures (unpublished) in digital format for sharing upon request	Humboldt-University of Berlin	Experimental Biophysics - Hegemann lab	Humboldt-University of Berlin
Materials	Homology models or X-ray structures (unpublished) in digital format for sharing upon request	Marcel Bermudez	Molecular Design Lab (Wolber lab)	Freie Universität Berlin
Materials	Homology models or X-ray structures (unpublished) in digital format for sharing upon request	Paula Morales/ Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute		Cannbinoid related orphan GPCRs
Materials	Homology models or X-ray structures (unpublished) in digital format for sharing upon request	Rafael Franco/ University of Barcelona	Molecular Nuerobiology	University of Barcelona		We have built models of GPCR heteromers, in collaboration with the research group of prof. Leonardo Pardo
Materials	In house (synthetic) chemical library/collection	Abdurrahman Olgac	Banoglu Research Group	Gazi University, Faculty of Pharmacy
Materials	In house (synthetic) chemical library/collection	Domain Therapeutics	Drug Discovery			BRET based technology PCREB Target engagment Biomarkers of efficacy
Materials	In house (synthetic) chemical library/collection	Eddy Sotelo	ComBioMed	CIQUS. University of Santiago de Compostela		A large collection of heterocyclic compounds
Materials	In house (synthetic) chemical library/collection	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg		library of heterocycles and peptides
Materials	In house (synthetic) chemical library/collection	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		large library of ligands for dopamine and histamine receptor subtypes and also on lipid signalling (arachidonic and sphingolipid pathways) - uncharacterized intermediates also available
Materials	In house (synthetic) chemical library/collection	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		Our research centre has a repository of original molecules that have been synthesised during med chem programs
Materials	In house (synthetic) chemical library/collection	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC		Libraries of ligands for diverse GPCRs like: -serotonin receptors -adenosine receptors -cannabinoid receptors (among them a Library of synthetic cannabinoid receptor agonists called SCRAs) -dopamine receptors
Materials	In house (synthetic) chemical library/collection	Nadine Jagerovic/Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute		Modulators of CB1, CB2 and cannabinoid related orphan GPCRs such as GPR55 or GPR18
Materials	In house (synthetic) chemical library/collection	Trond Vidar Hansen/ Department of Pharmacy, Section for Pharmaceutical Chemistry	LIPCHEM	Department of Pharmacy, Section for Pharmaceutical Chemistry, University of Oslo
Materials	Lead/Hit GPCR modulators	Anna Ardévol	MoBioFood	Universitat Rovira i Virgili		Tas2R agonists
Materials	Lead/Hit GPCR modulators	Domain Therapeutics	Drug Discovery			Agonists Antagonists Monoclonal anti bodies
Materials	Lead/Hit GPCR modulators	Eddy Sotelo	ComBioMed	CIQUS. University of Santiago de Compostela	e.sotelo	We have lead structures emerging from pur research programs: Adenosine receptors (A1, A2A, A2B, A3), D2 receptor family, Cannabinoids (CB1, CB2), 5HT2 receptor family,
Materials	Lead/Hit GPCR modulators	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg		antagonists of NPFF receptor
Materials	Lead/Hit GPCR modulators	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		many GPCR ligands, some multiple targeting ligands some highly selective chemical probes
Materials	Lead/Hit GPCR modulators	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		We have identified and developed original chemical tools to modulate the activity of the orphan GPCR GPR27.
Materials	Lead/Hit GPCR modulators	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC		Hit and lead modulators for: -serotonin receptors -adenosine receptors -cannabinoid receptors (among them a Library of synthetic cannabinoid receptor agonists called SCRAs) -dopamine receptors
Materials	Lead/Hit GPCR modulators	Nadine Jagerovic/Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute		compounds acting on the endocannabinoid system
Materials	Lead/Hit GPCR modulators	Trond Vidar Hansen/ Department of Pharmacy, Section for Pharmaceutical Chemistry	LIPCHEM	University of Oslo
Materials	Lead/Hit GPCR modulators	Véronique Bozon/University of Tours	BIOS	INRAe/University of Tours
Materials	Other	Domain Therapeutics	Drug Discovery			Knock in and knock out mice
Materials	Other	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg		softwares: ICHEM: C++, A toolkit to detect, analyze and compare protein-ligand interactions LID: tool to prioritize docking poses PROCARE, SHAPER and SITEALIGN: tools for protein binding site comparison
Materials	Other	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		MAO A/B, AChE, BuChE, ORAC, cell toxicity
Materials	Other	Humboldt-University of Berlin	Experimental Biophysics - Hegemann lab	Humboldt-University of Berlin		Rhodopsin-based and BLUF-domain based cAMP / cGMP modulating optogenetic enzymes, i.e. cyclases and PDEs if they are published already, otherwise case-dependent.
Materials	Other	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		Mouse lines for the study of GPCR
Materials	Target GPCRs	Abdurrahman Olgac	Banoglu Research Group	Gazi University, Faculty of Pharmacy
Materials	Target GPCRs	Ago Rinken	GPCR group	University of Tartu, Institute of Chemistry, Estonia		Baculovirus systems for several GPCR D1, D3, M1, M2, M4, MC4, NPY1, etc.
Materials	Target GPCRs	Anna Ardévol	MoBioFood	Universitat Rovira i Virgili		TASR
Materials	Target GPCRs	Antonios Kolocouris		National and Kapodistrian University of Athens		Adenosine receptors A1, A2A, A3 and A2B
Materials	Target GPCRs	Domain Therapeutics	Drug Discovery
Materials	Target GPCRs	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		H1R, H3R, H4R, D1R, D2R, D3R, D5R
Materials	Target GPCRs	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		We have several target currently under study, GPR101, GPR27, SUCNR1 & GPR85.
Materials	Target GPCRs	Marcel Bermudez	Molecular Design Lab (Wolber lab)	Freie Universität Berlin		Mainly muscarinic receptors, adenosine receptors, opioid receptors, but also all others.
Materials	Target GPCRs	Nadine Jagerovic/Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute		CB1; CB2; GPR55; GPR18; GPR6
Materials	Target GPCRs	Rafael Franco/ University of Barcelona	Molecular Nuerobiology	University of Barcelona		Cannabinoid, dopamine, adenosine & histamine receptors. Also sigma 1 receptor
Materials	Target GPCRs	Tommaso Patriarchi / University of Zurich	Patriarchi	University of Zurich		N/A
Materials	Target GPCRs	Véronique Bozon/University of Tours	BIOS	INRAe/University of Tours
Medicinal Chemistry	Chemical Analysis	Antonios Kolocouris		National and Kapodistrian University of Athens		1D and 2D NMR spectroscopy and mass-spectroscopy
Medicinal Chemistry	Chemical Analysis	Eddy Sotelo	ComBioMed	CIQUS. University of Santiago de Compostela	e.sotelo	In house most used analysis techiniques, IR, NMR, Crystalography, circular dichroism, HPLC, chiral HPLC,
Medicinal Chemistry	Chemical Analysis	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg
Medicinal Chemistry	Chemical Analysis	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		LC-MS, NMR, IR, elemental analysis, fluorescence, etc.
Medicinal Chemistry	Chemical Analysis	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège
Medicinal Chemistry	Chemical Analysis	Katarina Nikolic/University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy
Medicinal Chemistry	Chemical Analysis	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC		NMR, elemental analysis, HPLC analysis and chiral HPLC
Medicinal Chemistry	Chemical Analysis	Nadine Jagerovic/ Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute
Medicinal Chemistry	Chemical Analysis	Trond Vidar Hansen/ Department of Pharmacy, Section for Pharmaceutical Chemistry	LIPCHEM	University of Oslo
Medicinal Chemistry	In silico structure-based or ligand-based drug design/QSAR modeling	Abdurrahman Olgac	Banoglu Research Group	Gazi University, Faculty of Pharmacy
Medicinal Chemistry	In silico structure-based or ligand-based drug design/QSAR modeling	Antonios Kolocouris		National and Kapodistrian University of Athens		Against adenosine receptors; docking, MD simulations, binding free energy calculations (MM-PBSA, TI/MD etc)
Medicinal Chemistry	In silico structure-based or ligand-based drug design/QSAR modeling	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg
Medicinal Chemistry	In silico structure-based or ligand-based drug design/QSAR modeling	Katarina Nikolic/University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy		In silico structure-based (MD, VD, SB-VS) and ligand-based drug design/QSAR modeling (2D/3D-QSAR modeling, pharmacophore modeling, LB-VS, PB/VS).
Medicinal Chemistry	In silico structure-based or ligand-based drug design/QSAR modeling	Marcel Bermudez	Molecular Design Lab (Wolber lab)	Freie Universität Berlin		Structure-based virtual screening (pharmacophore-based and docking)
Medicinal Chemistry	In silico structure-based or ligand-based drug design/QSAR modeling	Nadine Jagerovic/ Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute
Medicinal Chemistry	Other
Medicinal Chemistry	Other Molecular Modeling activities	Abdurrahman Olgac	Banoglu Research Group	Gazi University, Faculty of Pharmacy
Medicinal Chemistry	Other Molecular Modeling activities	Antonios Kolocouris		National and Kapodistrian University of Athens		MD simulations
Medicinal Chemistry	Other Molecular Modeling activities	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg
Medicinal Chemistry	Other Molecular Modeling activities	Katarina Nikolic/University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy		In silico optimization of physicochemical and ADMET properties.
Medicinal Chemistry	Other Molecular Modeling activities	Marcel Bermudez	Molecular Design Lab (Wolber lab)	Freie Universität Berlin		MD simulations and dynamic interaction pattern (dynophores)
Medicinal Chemistry	Other Molecular Modeling activities	Paula Morales/ Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute		Docking, MD, scaffold hopping, etc (for cannabinoid related GPCRs)
Medicinal Chemistry	Other Molecular Modeling activities	Rafael Franco/ University of Barcelona	Molecular Nuerobiology	University of Barcelona		In collaboratin with the research group of Leonardo Pardo we explore orthosteric and allosteric/exosites in GPCRs.
Medicinal Chemistry	Preformulation studies	Antonios Kolocouris		National and Kapodistrian University of Athens		We are in contact with pharmaceutical technology experts in our Department of Pharmacy
Medicinal Chemistry	Preformulation studies	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		can be performed in house, bnut has rarely been done - equipment and experts are available
Medicinal Chemistry	Preformulation studies	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège
Medicinal Chemistry	Preformulation studies	Trond Vidar Hansen/ Department of Pharmacy, Section for Pharmaceutical Chemistry	LIPCHEM	University of Oslo
Medicinal Chemistry	Scale-up of optimized compounds	Antonios Kolocouris		National and Kapodistrian University of Athens		Able to gram scale synthesis
Medicinal Chemistry	Scale-up of optimized compounds	Eddy Sotelo	ComBioMed	CIQUS. University of Santiago de Compostela	e.sotelo
Medicinal Chemistry	Scale-up of optimized compounds	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg
Medicinal Chemistry	Scale-up of optimized compounds	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		in some cases performed
Medicinal Chemistry	Scale-up of optimized compounds	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège
Medicinal Chemistry	Scale-up of optimized compounds	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC
Medicinal Chemistry	Scale-up of optimized compounds	Nadine Jagerovic/ Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute
Medicinal Chemistry	Scale-up of optimized compounds	Trond Vidar Hansen/ Department of Pharmacy, Section for Pharmaceutical Chemistry	LIPCHEM	University of Oslo
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Antonios Kolocouris		National and Kapodistrian University of Athens		We are working on the synthesis of potential A3R antagonists; a colleague can undertake the synthesis of nucleoside derivatives as agonists
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Eddy Sotelo	ComBioMed	CIQUS. University of Santiago de Compostela	e.sotelo	Experience in most part of MedChem process: targeted oriented synthesis, DOS, hit discovery and optimization, lead optimization, ADME optimization.
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		different lead optimizations, different functionalisation of potent ligands
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Katarina Nikolic/University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC		-Expertise in hit generation and hit to lead optimization; -preparation of big chemical libraries.
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Nadine Jagerovic/ Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Rafael Franco/ University of Barcelona	Molecular Nuerobiology	University of Barcelona		In collaboratin with the research group of Leonardo Pardo we explore new ligands (after desgin and syntesis) for orthosteric and allosteric/exosites in GPCRs.
Medicinal Chemistry	Synthetic Medicinal chemistry: hit/lead compounds	Trond Vidar Hansen/ Department of Pharmacy, Section for Pharmaceutical Chemistry	LIPCHEM	University of Oslo
Preclinical candidate development	API Manufacturing	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC
Preclinical candidate development	API Process Development	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC
Preclinical candidate development	API Process Development	Trond Vidar Hansen/ Department of Pharmacy, Section for Pharmaceutical Chemistry	LIPCHEM	University of Oslo
Preclinical candidate development	Bioanalytical method development	Ago Rinken	GPCR group	University of Tartu, Institute of Chemistry, Estonia		Detection of hormones based on GPCR - linked assays
Preclinical candidate development	Bioanalytical method development	Anna Ardévol	MoBioFood	Universitat Rovira i Virgili		Intestinal screening methodologies
Preclinical candidate development	Bioanalytical method development	Antonios Kolocouris		National and Kapodistrian University of Athens		Pharmacokinetics in mice using mass spectroscopy
Preclinical candidate development	Bioanalytical method development	Humboldt-University of Berlin	Experimental Biophysics - Hegemann lab	Humboldt-University of Berlin		bioluminescent cGMP measurements
Preclinical candidate development	Bioanalytical method development	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège
Preclinical candidate development	Bioanalytical method development	Tommaso Patriarchi / University of Zurich	Patriarchi	University of Zurich
Preclinical candidate development	DRF/MTD: preliminary non-GLP tox study in a rodent and a non-rodent species
Preclinical candidate development	Drug Product Supply	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège
Preclinical candidate development	Drug Product Supply	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC
Preclinical candidate development	Extended compound profiling: Receptors, ion channels, enzymes, CYP, hERG
Preclinical candidate development	In vitro Genetic tox studies
Preclinical candidate development	In vitro metabolism in hepatocytes	Anna Ardévol	MoBioFood	Universitat Rovira i Virgili		HEP-G2
Preclinical candidate development	Other	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		Advisory Board member of phase I clinical trials on Alzheimer drugs
Preclinical candidate development	PK study in the non-rodent tox species
Preclinical candidate development	Preliminary Formulation Development	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège
Screening activity	Computational virtual screening (CADD, machine learning)	Abdurrahman Olgac	Banoglu Research Group	Gazi University, Faculty of Pharmacy
Screening activity	Computational virtual screening (CADD, machine learning)	Antonios Kolocouris		National and Kapodistrian University of Athens		Against adenosine receptors
Screening activity	Computational virtual screening (CADD, machine learning)	Esther Kellenberger & Frédéric Bihel	Chemogenomics and medicinal chemistry	UMR7200 CNRS University of Strasbourg		docking, pharmacophore, data mining fragment-based approach
Screening activity	Computational virtual screening (CADD, machine learning)	Katarina Nikolic/University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy		https://doi.org/10.1002/minf.201900165 Based on our previously developed methodology (https://doi.org/10.1002/minf.201900165) we are now examining newly synthesized GPCR ligands.
Screening activity	Computational virtual screening (CADD, machine learning)	Marcel Bermudez	Molecular Design Lab (Wolber lab)	Freie Universität Berlin		Structure-based virtual screening (pharmacophore-based and docking)
Screening activity	Computational virtual screening (CADD, machine learning)	Nadine Jagerovic/ Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute
Screening activity	Developing novel GPCR-based screening	Ago Rinken	GPCR group	University of Tartu, Institute of Chemistry, Estonia		Different fluorescent-based assays Live cell imaging (incl kinetics) Ultrasensitive TIRF based detection of ligand binding Gx connected pathway activation
Screening activity	Developing novel GPCR-based screening	Domain Therapeutics	Drug Discovery
Screening activity	Developing novel GPCR-based screening	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		Binding kinetics at H3R and D3R
Screening activity	Developing novel GPCR-based screening	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		We have a track-record of new original assays, notably to detect arrestin (see Dupuis et al Molecular Pharmacology 2017 PMID: 28314853) and G protein interactions (see Laschet et al. JBC, 2019, PMID: 30593506). These assays are compatible with screening.
Screening activity	Developing novel GPCR-based screening	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC		We are able to develop fluorescent ligands for novel GPCR-based screening
Screening activity	Existing GPCR-based screening	Ago Rinken	GPCR group	University of Tartu, Institute of Chemistry, Estonia		Ligand binding using FA assay Live cell imaging
Screening activity	Existing GPCR-based screening	Domain Therapeutics	Drug Discovery
Screening activity	Existing GPCR-based screening	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		H1R, H3R, H4R, D1R, D2R, D3R, D5R
Screening activity	Existing GPCR-based screening	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		We have developed and use successfully many GPCR assays (see Dupuis et al Molecular Pharmacology 2017 PMID: 28314853 and Laschet et al. JBC, 2019, PMID: 30593506.
Screening activity	Existing GPCR-based screening	Maria Majellaro/ Celtarys Research-CIQUS-USC	Celtrays Research-ComBioMed Group	CIQUS-USC		We are able to develop fluorescent ligands for existing GPCR-based screening
Screening activity	Existing GPCR-based screening	Rafael Franco/ University of Barcelona	Molecular Nuerobiology	University of Barcelona		Signaling assays (diverse). Also effect of toxins and minigenes/peptides disrupting G coupling
Screening activity	High throughput screen/assay	Ago Rinken	GPCR group	University of Tartu, Institute of Chemistry, Estonia		FA based assay on the 384 well plates
Screening activity	High throughput screen/assay	Domain Therapeutics	Drug Discovery
Screening activity	High throughput screen/assay	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		We have developed and use successfully many GPCR assays in screening context (see Dupuis et al Molecular Pharmacology 2017 PMID: 28314853 and Laschet et al. JBC, 2019, PMID: 30593506)
Screening activity	High throughput screen/assay	Tommaso Patriarchi / University of Zurich	Patriarchi	University of Zurich
Screening activity	In vitro ADME-Tox profiling (Drug-likeness assessment)	Katarina Nikolic/University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy		In vitro ADMET profiling: Based on our previously developed in vitro methodology (http://dx.doi.org/10.1016/j.ejps.2014.12.014, http://dx.doi.org/10.1016/j.jpba.2016.02.053) we are now examining GPCR ligands and related compounds.
Screening activity	In vitro ADME-Tox profiling (Drug-likeness assessment)	Marcel Bermudez	Molecular Design Lab (Wolber lab)	Freie Universität Berlin
Screening activity	In vitro ADME-Tox profiling (Drug-likeness assessment)	Nadine Jagerovic/ Spanish Research Council	Modulators of the Endocannabinoid System	Medicinal Chemistry Institute
Screening activity	In vivo models: efficacy, PK, PD	Anna Ardévol	MoBioFood	Universitat Rovira i Virgili		Modulation of Food Intake by Differential TAS2R Stimulation in Rat Grau-Bové C, Miguéns-Gómez A, Gonzalez-Quilen, C, Fernández-López JA, Remesar X, Torres-Fuentes C, Ávila-Román J, Rodríguez-Gallego E, Beltrán-Debón R, Blay M, Terra X, Ardévol A, Pinent M. Nutrients. 2020;12(12):E3784. https://https://doi.org/10.3390/nu12123784. PMID: 33260866 Free article
Screening activity	In vivo models: efficacy, PK, PD	Domain Therapeutics	Drug Discovery			KI and KO mice
Screening activity	In vivo models: efficacy, PK, PD	Julien Hanson/University of Liège	Laboratory of Molecular Pharmacology	University of Liège		We have developed mouse lines but not for the evaluation of efficacy, PK and PD specifically. But we have the expertise on in vivo pharmacology.
Screening activity	In vivo models: efficacy, PK, PD	Tommaso Patriarchi / University of Zurich	Patriarchi	University of Zurich
Screening activity	Other	Katarina Nikolic/University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy	Department of Pharmaceutical chemistry, University of Belgrade, Faculty of Pharmacy		Based on our previously developed in silico methodology (http://dx.doi.org/10.1016/j.ejps.2014.12.014, http://dx.doi.org/10.1016/j.jpba.2016.02.053) we are now examining GPCR ligands and related compounds.
Screening activity	Other bioactivity screening	Ago Rinken	GPCR group	University of Tartu, Institute of Chemistry, Estonia		cAMP activation in cells cell viability resazurine based assay
Screening activity	Other bioactivity screening	Domain Therapeutics	Drug Discovery			pCREB Cytokines
Screening activity	Other bioactivity screening	Holger Stark/ Heinrich Heine University Düsseldorf	Stark - Lab	Institute of Pharmaceutical and Medicinal Chemistry		MAO A/B, AChE, BuChE, ORAC, cell toxicity, others are in preparation
Screening activity	Other bioactivity screening	Humboldt-University of Berlin	Experimental Biophysics - Hegemann lab	Humboldt-University of Berlin		ELISA-based cGMP measurements at low concentrations down to 100 pM, electrophysiology with cGMP ion channels, luminescent cGMP measurements
Screening activity	Other bioactivity screening	Tommaso Patriarchi / University of Zurich	Patriarchi	University of Zurich